Evidence map›Paper›PMID 40552137›Full record

ArticleBlood neoplasia2024

Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells.

Anne P de Groot, Chelsea R Wilson, Ellen Weersing, Jacobine S Pouw, Albertina Dethmers-Ausema, Huong Nguyen, Evan F W Chen, Alok Shaurya, Linda Smit, Fraser Hof and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anne P de GrootEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, The Netherlands.
Chelsea R WilsonDepartment of Chemistry, University of Victoria, Victoria, BC, Canada.
Ellen WeersingEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, The Netherlands.
Jacobine S PouwDepartment of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
Albertina Dethmers-AusemaEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, The Netherlands.
Huong NguyenEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, The Netherlands.
Evan F W ChenDepartment of Chemistry, University of Victoria, Victoria, BC, Canada.
Alok ShauryaDepartment of Chemistry, University of Victoria, Victoria, BC, Canada.
Linda SmitDepartment of Hematology, Amsterdam University Medical Center, Location Vrije Universiteit Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Fraser HofDepartment of Chemistry, University of Victoria, Victoria, BC, Canada.
Gerald de HaanEuropean Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Self-renewal of leukemic cells results in the accumulation of dysfunctional blood cells and suppression of normal hematopoiesis. The polycomb group protein chromobox 7 (CBX7) is an epigenetic regulator that represses genes required for differentiation and cell cycle arrest and thereby promotes self-renewal. Because leukemic cells are highly self-renewing, we tested whether pharmacological targeting of CBX7 would reduce self-renewal and induce differentiation of human leukemic cells. We found that existing and newly developed CBX7 inhibitors derepress the epigenome, resulting in reduced ubiquitination of histone 2A and reduced binding of CBX7 to its target genes. This led to reduced cell growth, increased differentiation of leukemic cells in vitro, and delayed engraftment of primary leukemic cells in xenotransplant models. Therefore, pharmacological targeting of CBX7 constitutes a novel therapeutic approach for leukemia.

Identifiers

PMID40552137
PMCPMC12182855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.